Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Mirum Pharmaceuticals Inc (MIRM)

Mirum Pharmaceuticals Inc (MIRM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,614,219
  • Shares Outstanding, K 60,342
  • Annual Sales, $ 521,310 K
  • Annual Income, $ -23,360 K
  • EBIT $ -22 M
  • EBITDA $ 4 M
  • 60-Month Beta 0.52
  • Price/Sales 10.16
  • Price/Cash Flow 1,722.27
  • Price/Book 14.34

Options Overview Details

View History
  • Implied Volatility 59.22% (+3.00%)
  • Historical Volatility 59.10%
  • IV Percentile 93%
  • IV Rank 71.48%
  • IV High 70.14% on 04/10/25
  • IV Low 31.86% on 08/21/25
  • Expected Move (DTE 15) 7.99 (8.90%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 74
  • Put/Call OI Ratio 0.61
  • Today's Open Interest 1,770
  • Open Int (30-Day) 1,359
  • Expected Range 81.83 to 97.81

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.36
  • Number of Estimates 5
  • High Estimate -0.18
  • Low Estimate -0.56
  • Prior Year -0.30
  • Growth Rate Est. (year over year) -20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
87.60 +2.64%
on 03/03/26
109.28 -17.73%
on 02/24/26
-8.32 (-8.47%)
since 02/05/26
3-Month
63.23 +42.19%
on 12/15/25
109.28 -17.73%
on 02/24/26
+21.43 (+31.29%)
since 12/05/25
52-Week
36.88 +143.79%
on 04/09/25
109.28 -17.73%
on 02/24/26
+45.27 (+101.41%)
since 03/05/25

Most Recent Stories

More News
Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus

- Phase 3 AZURE-1 enrollment complete - Phase 3 AZURE-4 screening complete - Topline AZURE-1 and AZURE-4 results expected in...

MIRM : 89.23 (-4.10%)
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update

- 2025 net product sales of $521 million - 2026 expected global net product sales of $630 million to $650 million - Volixibat...

MIRM : 89.23 (-4.10%)
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will participate in the following upcoming investor conferences: ...

MIRM : 89.23 (-4.10%)
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it will report fourth quarter and year-end 2025 financial results on February 25, 2026. Mirum will also host a conference call to discuss...

MIRM : 89.23 (-4.10%)
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on February 10, 2026, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock...

MIRM : 89.23 (-4.10%)
Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome

- Tablet authorization builds upon established use of LIVMARLI oral solution in Canada

MIRM : 89.23 (-4.10%)
Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC)

- Authorization includes oral solution and tablet formulation to support flexible dosing

MIRM : 89.23 (-4.10%)
Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease

- Adds brelovitug for chronic hepatitis delta virus (HDV) with Breakthrough Therapy and PRIME designations to Mirum’s portfolio - Topline Phase 3 results expected...

MIRM : 89.23 (-4.10%)
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on January 9, 2026, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock...

MIRM : 89.23 (-4.10%)
Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth and Pipeline Momentum

- 2025 net product sales of approximately $520 million (preliminary and unaudited) exceed upper end of guidance - 2026 expected global net product sales of $630...

MIRM : 89.23 (-4.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Mirum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company's product candidate consists of maralixibat, an investigational oral drug in development...

See More

Key Turning Points

3rd Resistance Point 100.36
2nd Resistance Point 96.81
1st Resistance Point 94.93
Last Price 89.23
1st Support Level 89.50
2nd Support Level 85.95
3rd Support Level 84.07

See More

52-Week High 109.28
Last Price 89.23
Fibonacci 61.8% 81.62
Fibonacci 50% 73.08
Fibonacci 38.2% 64.54
52-Week Low 36.88

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar